Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Cooperation process between a local government and experts in official voluntary decontamination of environmental radioactivity.

Iimoto T, Fujii H, Someya S, Matsuzawa H, Yanagawa Y, Kunii K.

J Radiat Res. 2018 Apr 1;59(suppl_2):ii48-ii53. doi: 10.1093/jrr/rry016.

2.

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.

Marjon K, Cameron MJ, Quang P, Clasquin MF, Mandley E, Kunii K, McVay M, Choe S, Kernytsky A, Gross S, Konteatis Z, Murtie J, Blake ML, Travins J, Dorsch M, Biller SA, Marks KM.

Cell Rep. 2016 Apr 19;15(3):574-587. doi: 10.1016/j.celrep.2016.03.043. Epub 2016 Apr 7.

3.

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.

Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, Corson L, Feala J, Fekkes P, Ichikawa K, Keaney GF, Lee L, Kumar P, Kunii K, MacKenzie C, Matijevic M, Mizui Y, Myint K, Park ES, Puyang X, Selvaraj A, Thomas MP, Tsai J, Wang JY, Warmuth M, Yang H, Zhu P, Garcia-Manero G, Furman RR, Yu L, Smith PG, Buonamici S.

Cell Rep. 2015 Nov 3;13(5):1033-45. doi: 10.1016/j.celrep.2015.09.053. Epub 2015 Oct 22.

4.

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK.

Science. 2013 May 3;340(6132):626-30. doi: 10.1126/science.1236062. Epub 2013 Apr 4.

5.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK.

Transl Oncol. 2012 Dec;5(6):422-9. Epub 2012 Dec 1.

6.

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F, Gross S, Dang L, Yen KE, Yang H, Straley KS, Jin S, Kunii K, Fantin VR, Zhang S, Pan Q, Shi D, Biller SA, Su SM.

ACS Med Chem Lett. 2012 Sep 17;3(10):850-5. doi: 10.1021/ml300225h. eCollection 2012 Oct 11.

7.

Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.

Kung C, Hixon J, Choe S, Marks K, Gross S, Murphy E, DeLaBarre B, Cianchetta G, Sethumadhavan S, Wang X, Yan S, Gao Y, Fang C, Wei W, Jiang F, Wang S, Qian K, Saunders J, Driggers E, Woo HK, Kunii K, Murray S, Yang H, Yen K, Liu W, Cantley LC, Vander Heiden MG, Su SM, Jin S, Salituro FG, Dang L.

Chem Biol. 2012 Sep 21;19(9):1187-98. doi: 10.1016/j.chembiol.2012.07.021.

8.

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.

Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park HW, Cantley LC, Thomas CJ, Vander Heiden MG.

Nat Chem Biol. 2012 Oct;8(10):839-47. Erratum in: Nat Chem Biol. 2012 Dec;8(12):1008.

9.

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.

Katz JD, Jewell JP, Guerin DJ, Lim J, Dinsmore CJ, Deshmukh SV, Pan BS, Marshall CG, Lu W, Altman MD, Dahlberg WK, Davis L, Falcone D, Gabarda AE, Hang G, Hatch H, Holmes R, Kunii K, Lumb KJ, Lutterbach B, Mathvink R, Nazef N, Patel SB, Qu X, Reilly JF, Rickert KW, Rosenstein C, Soisson SM, Spencer KB, Szewczak AA, Walker D, Wang W, Young J, Zeng Q.

J Med Chem. 2011 Jun 23;54(12):4092-108. doi: 10.1021/jm200112k. Epub 2011 May 24.

PMID:
21608528
10.

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.

Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, Nagashima K, O'Hare E, Erkul Y, Di Bacco A, Gargano D, Shomer NH, Angagaw M, Leccese E, Andrade P, Hurd M, Shin MK, Vogt TF, Northrup A, Bobkova EV, Kasibhatla S, Bronson RT, Scott ML, Draetta G, Richon V, Kohl N, Blume-Jensen P, Andersen JN, Kraus M.

Cancer Res. 2011 Apr 15;71(8):3052-65. doi: 10.1158/0008-5472.CAN-10-2282.

11.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ.

Cancer Res. 2010 Feb 15;70(4):1524-33. doi: 10.1158/0008-5472.CAN-09-2541. Epub 2010 Feb 9.

12.

Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.

Tammam J, Ware C, Efferson C, O'Neil J, Rao S, Qu X, Gorenstein J, Angagaw M, Kim H, Kenific C, Kunii K, Leach KJ, Nikov G, Zhao J, Dai X, Hardwick J, Scott M, Winter C, Bristow L, Elbi C, Reilly JF, Look T, Draetta G, Van der Ploeg L, Kohl NE, Strack PR, Majumder PK.

Br J Pharmacol. 2009 Nov;158(5):1183-95. doi: 10.1111/j.1476-5381.2009.00389.x. Epub 2009 Sep 23.

13.

Haemangioma of the forehead: radiographic diagnosis and definitive surgical treatment in a Japanese series.

Satoh K, Ohtsuka T, Abe T, Yokota K, Kunii K.

Scand J Plast Reconstr Surg Hand Surg. 2009;43(2):75-81. doi: 10.1080/02844310802602358.

PMID:
19308857
14.

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B.

Cancer Res. 2008 Apr 1;68(7):2340-8. doi: 10.1158/0008-5472.CAN-07-5229. Erratum in: Cancer Res. 2008 May 1;68(9):3550.

15.

A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice.

Fujimoto M, Shimizu N, Kunii K, Martyn JA, Ueki K, Kaneki M.

Diabetes. 2005 May;54(5):1340-8.

16.

Orexin-mediated feeding behavior involves both leptin-sensitive and -insensitive pathways.

Zhu Y, Yamanaka A, Kunii K, Tsujino N, Goto K, Sakurai T.

Physiol Behav. 2002 Nov;77(2-3):251-7.

PMID:
12419401
17.

Type II phosphatidylinositol 4-kinase beta is a cytosolic and peripheral membrane protein that is recruited to the plasma membrane and activated by Rac-GTP.

Wei YJ, Sun HQ, Yamamoto M, Wlodarski P, Kunii K, Martinez M, Barylko B, Albanesi JP, Yin HL.

J Biol Chem. 2002 Nov 29;277(48):46586-93. Epub 2002 Sep 24.

18.

Involvement of the serotonergic system in orexin-induced behavioral alterations in rats.

Matsuzaki I, Sakurai T, Kunii K, Nakamura T, Yanagisawa M, Goto K.

Regul Pept. 2002 Mar 15;104(1-3):119-23.

PMID:
11830286
19.

A new extraction method for Acinetobacter species ODB-L2 rough form lipopolysaccharide from culture broth.

Kunii K, Nakamura S, Sato C, Fukuoka S.

Microbios. 2001;105(412):153-61.

PMID:
11414500
20.

Orexin-induced food intake involves neuropeptide Y pathway.

Yamanaka A, Kunii K, Nambu T, Tsujino N, Sakai A, Matsuzaki I, Miwa Y, Goto K, Sakurai T.

Brain Res. 2000 Mar 24;859(2):404-9.

PMID:
10719096
21.

Orexins/hypocretins regulate drinking behaviour.

Kunii K, Yamanaka A, Nambu T, Matsuzaki I, Goto K, Sakurai T.

Brain Res. 1999 Sep 18;842(1):256-61.

PMID:
10526122
22.

Concentration of levofloxacin in cervical mucus and its clinical effects on cervicitis.

Chimura T, Arai M, Onuma Y, Oda T, Kawagoe S, Kunii K, Saito T, Saito N, Sato F, Numazaki M, Matsuo M, Murayama K, Morizaki N.

Jpn J Antibiot. 1997 Nov;50(11):871-7.

PMID:
9651605
23.

Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q-35) in obstetrics and gynaecology.

Cho N, Miyakawa Z, Kimura T, Shimizu A, Notake Y, Kunii K.

Drugs. 1995;49 Suppl 2:391-2. No abstract available.

PMID:
8549373
24.

[Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology].

Cho N, Araki H, Kimura T, Shimizu A, Ichikawa K, Fukunaga K, Kunii K.

Jpn J Antibiot. 1992 Mar;45(3):270-84. Japanese.

PMID:
1512924
25.

[Studies on flomoxef in the perinatal period].

Cho N, Fukunaga K, Kunii K, Kobayashi I.

Jpn J Antibiot. 1991 Jun;44(6):674-82. Japanese.

PMID:
1890728
26.

[Studies on aztreonam in the perinatal period].

Cho N, Fukunaga K, Kunii K, Kobayashi I.

Jpn J Antibiot. 1990 Apr;43(4):706-18. Japanese.

PMID:
2116538
27.

[Fundamental and clinical studies on cefmenoxime in perinatal period].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1989 Dec;42(12):2692-708. Japanese.

PMID:
2614922
28.

[Pharmacokinetic studies on cefsulodin in perinatal period].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1989 Dec;42(12):2735-42. Japanese.

PMID:
2515321
29.

[Pharmacokinetic and clinical studies on cefodizime in obstetrics and gynecology].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1989 Oct;42(10):2069-81. Japanese.

PMID:
2607597
30.

[Studies on imipenem/cilastatin sodium in the perinatal period].

Cho N, Fukunaga K, Kunii K, Kobayashi I, Tezuka K.

Jpn J Antibiot. 1988 Nov;41(11):1758-73. Japanese.

PMID:
3062206
31.

[Studies of ceftizoxime in perinatal period].

Cho N, Fukunaga K, Kunii K, Tezuka K, Kobayashi I.

Jpn J Antibiot. 1988 Aug;41(8):1142-54. Japanese.

PMID:
3050194
32.

[Bacteriological, pharmacokinetic and clinical studies on the use of ceftriaxone in the perinatal period].

Cho N, Fukunaga K, Kunii K, Deguchi K.

Jpn J Antibiot. 1988 Feb;41(2):180-95. Japanese.

PMID:
3286925
33.

[Pharmacokinetic and clinical studies on cefuzonam in obstetrics and gynecology].

Cho N, Fukunaga K, Kunii K, Kimura T, Kameda S, Watanabe H.

Jpn J Antibiot. 1987 May;40(5):1007-28. Japanese.

PMID:
3669280
34.

[Clinical studies of BRL 28500 (clavulanic acid/ticarcillin) in the treatment of pelvioperitonitis and Douglas' abscess].

Matsuda S, Suzuki M, Miyazaki R, Cho N, Kunii K, Fukunaga K, Hayashi S, Nakamura H, Tateno M, Okada H, et al.

Jpn J Antibiot. 1987 May;40(5):951-68. Japanese.

PMID:
3499526
35.

[Pharmacokinetic and clinical studies of cefotiam in the perinatal period].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1986 Sep;39(9):2488-96. Japanese.

PMID:
3467090
36.

[Pharmacokinetic and clinical studies of ceftazidime in perinatal period].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1986 Aug;39(8):2225-46. Japanese.

PMID:
3540354
37.

[Fundamental and clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1986 May;39(5):1359-71. Japanese.

PMID:
3463782
38.

[Clinical evaluation of aztreonam in the field of obstetrics and gynecology].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1985 Dec;38(12):3561-72. Japanese.

PMID:
3834139
39.

[Fundamental and clinical studies on fosfomycin sodium in the field of obstetrics and gynecology].

Cho N, Daito S, Sekiya M, Chin I, Fukunaga K, Kunii K.

Jpn J Antibiot. 1985 Aug;38(8):2045-56. Japanese.

PMID:
4078999
40.

[Pharmacokinetics and clinical studies on cefminox in the field of obstetrics and gynecology].

Cho N, Mitsukawa M, Aoki K, Togo M, Tamura T, Kunii K, Fukunaga K.

Jpn J Antibiot. 1985 May;38(5):1213-24. Japanese.

PMID:
3930789
41.

[Pharmacokinetics and clinical studies on cefpimizole in the field of obstetrics and gynecology].

Cho N, Fukunaga K, Kunii K.

Jpn J Antibiot. 1985 Apr;38(4):926-39. Japanese.

PMID:
4032730
42.

[Pharmacokinetics and clinical studies on ceftriaxone in the field of obstetrics and gynecology].

Cho N, Watanabe H, Yoshida K, Moriyama S, Takeda H, Tsukamoto A, Fukunaga K, Kunii K, Komoriyama Y.

Jpn J Antibiot. 1984 Dec;37(12):2304-19. Japanese.

PMID:
6098723
43.

[Fundamental and clinical studies on sulbactam/cefoperazone in the field of obstetrics and gynecology].

Cho N, Watanabe H, Yoshida K, Moriyama S, Takeda H, Tsukamoto A, Fukunaga K, Kunii K.

Jpn J Antibiot. 1984 Oct;37(10):1939-55. Japanese.

PMID:
6094873
44.
45.

[Clinical evaluation of tinidazole on anaerobic infections in the field of obstetrics and gynecology].

Cho N, Fukunaga K, Kunii K, Deguchi K.

Jpn J Antibiot. 1983 Dec;36(12):3325-35. Japanese.

PMID:
6674545
46.

[Basic and clinical studies on ceftazidime in the field of obstetrics and gynecology].

Cho N, Hara Y, Noguchi Y, Kondo H, Murakami M, Seki M, Maruyama M, Aoki K, Fukunaga K, Kunii K.

Jpn J Antibiot. 1983 Dec;36(12):3463-75. Japanese.

PMID:
6371294
47.

[Experimental and clinical evaluation of cefroxadine in the field of obstetrics and gynecology].

Cho N, Araki H, Ishikawa T, Kunii K, Fukunaga K, Deguchi K.

Jpn J Antibiot. 1983 Sep;36(9):2535-48. Japanese.

PMID:
6655868
48.

[Clinical application of latamoxef during the perinatal period].

Cho N, Suzuki H, Akiyama T, Kawamura E, Togo M, Nishimoto S, Hidaka T, Fukunaga K, Kunii K.

Jpn J Antibiot. 1983 Sep;36(9):2395-404. Japanese.

PMID:
6655858
49.

[Fundamental and clinical studies of T-1982 (cefbuperazone) in the field of obstetrics and gynecology].

Cho N, Fukunaga K, Kunii K, Deguchi K.

Jpn J Antibiot. 1983 May;36(5):939-55. Japanese.

PMID:
6352987
50.

Supplemental Content

Support Center